BCYC vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a remarkable 338.5% year-over-year revenue growth and strong analyst target price of $21.50 implying 210% upside, the company continues to report deep operating losses (-558.64% operating margin), deteriorating earnings (YoY EPS growth of -18.1%), and inconsistent earnings surprises, with only 1 out of the last 4 quarters beating estimates. High valuation multiples (Price/Sales of 17.01) contrast with negative profitability and weak insider sentiment, while recent insider selling adds downward pressure. Although the balance sheet appears strong with a current ratio of 10.66 and minimal debt, the lack of profitability and cash flow transparency limits confidence in sustainable recovery.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BCYC vs LLY: Head-to-Head Comparison
This page compares Bicycle Therapeutics plc (BCYC) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.